Wolff-Parkinson-White Disease (WPW)

01Pathophysiology

In a normal heart, the AV node is the only electrical bridge between the atria and the ventricles. It introduces a brief conduction delay that allows the atria to finish contracting before the ventricles fire. In WPW, an accessory pathway called the Bundle of Kent forms an extra electrical connection that bypasses the AV node entirely. This pathway is a remnant of embryonic tissue that failed to regress during fetal cardiac development.

Because the accessory pathway lacks the built-in delay of the AV node, electrical impulses traveling through it reach the ventricular myocardium earlier than expected. This is called pre-excitation. The part of the ventricle closest to the accessory pathway depolarizes prematurely through regular myocardial cells rather than through the fast-conducting His-Purkinje system. This slow cell-to-cell spread creates the delta wave, which is the hallmark slurred upstroke at the beginning of the QRS complex. The PR interval is short because the impulse did not wait at the AV node, and the QRS is wide because ventricular activation is a fusion of the early, slow pre-excited wavefront and the later, normal wavefront arriving through the AV node and Purkinje fibers.

The real clinical danger arises because the accessory pathway creates the substrate for re-entrant tachycardias. A re-entrant circuit forms when an impulse can travel down one pathway and loop back up the other, creating a self-sustaining circular rhythm. In orthodromic AVRT, the impulse travels down through the AV node (antegrade) and returns up through the accessory pathway (retrograde). Because ventricular depolarization occurs through the normal His-Purkinje system in this circuit, the resulting tachycardia has a narrow QRS complex. In antidromic AVRT, the impulse travels down through the accessory pathway and returns up through the AV node, producing a wide QRS complex because the ventricle depolarizes abnormally.

The most dangerous scenario is atrial fibrillation with a pre-excited ventricular response. During atrial fibrillation, hundreds of chaotic impulses bombard both the AV node and the accessory pathway. Unlike the AV node, most accessory pathways have a very short refractory period and can conduct impulses to the ventricles at extremely high rates, sometimes exceeding 300 beats per minute. This rapid, uncontrolled ventricular rate can degenerate into ventricular fibrillation and sudden cardiac death. This is why AV nodal blocking agents are strictly contraindicated: blocking the AV node forces all conduction through the unprotected accessory pathway, worsening the situation.

02Classification and Clinical Manifestation

Arrhythmia Types in WPW Syndrome

03Diagnostic Workup

The 12-lead ECG is the best initial test and is often sufficient to make the clinical diagnosis. The three hallmark findings are the delta wave (a slurred, gradual upstroke at the very beginning of the QRS), a short PR interval (less than $120ms120\backslash \; ms$, reflecting the bypass of AV nodal delay), and a widened QRS complex (greater than $120ms120\backslash \; ms$, due to the fusion of pre-excited and normally conducted ventricular activation). These findings are present at baseline during sinus rhythm and represent the "WPW pattern." If the patient is currently in tachycardia, the ECG during the episode will show either a narrow-complex regular tachycardia (orthodromic AVRT), a wide-complex regular tachycardia (antidromic AVRT), or an irregular wide-complex tachycardia (pre-excited AF).

An important caveat is that the accessory pathway may conduct only intermittently. In such cases, pre-excitation can appear and disappear on serial ECGs. This is why ambulatory monitoring with a Holter monitor or event recorder is valuable when symptoms are episodic but the resting ECG is normal.

The electrophysiology (EP) study is the gold standard. It is an invasive catheter-based procedure that precisely maps the location of the accessory pathway, measures its antegrade and retrograde refractory periods, and determines the risk of rapid conduction during atrial fibrillation. The EP study is not just diagnostic but also therapeutic, as it directly precedes radiofrequency catheter ablation. An EP study is indicated when the patient is symptomatic with arrhythmias, when catheter ablation is planned, or when risk stratification is needed in an asymptomatic patient with a high-risk occupation (e.g., pilots, competitive athletes).

Echocardiography should be obtained to evaluate for structural heart disease, particularly Ebstein anomaly, which has a well-established association with WPW. In Ebstein anomaly, the accessory pathway is typically right-sided.

04Management and Treatment

Acute Stabilization

For any patient presenting with a tachyarrhythmia and hemodynamic instability (hypotension, altered mental status, chest pain, or acute heart failure), the next best step is always immediate synchronized cardioversion regardless of the arrhythmia type.

In stable orthodromic AVRT (narrow-complex, regular tachycardia), initial management mirrors other SVTs: start with vagal maneuvers (Valsalva maneuver or carotid sinus massage), followed by adenosine if vagal maneuvers fail. Adenosine is given as a rapid 6 mg IV bolus through a large proximal vein, followed immediately by a saline flush. If the first dose is ineffective, a second dose of 12 mg is given. Adenosine works here because it transiently blocks the AV node, which is a critical limb of the orthodromic re-entrant circuit.

In stable antidromic AVRT (wide-complex, regular tachycardia), the preferred agent is IV procainamide. It is administered at a rate of 20 to 50 mg per minute until the arrhythmia terminates, the QRS widens by more than 50% of its original width, hypotension occurs, or a maximum total dose of 17 mg/kg is reached. Procainamide slows conduction through the accessory pathway itself, making it effective and safe.

The highest-stakes management scenario is atrial fibrillation with pre-excitation. This is the irregular, wide-complex tachycardia that can kill. The treatment is procainamide or ibutilide (1 mg IV infused over 10 minutes; a second dose can be given 10 minutes after the first if needed). If the patient does not respond or becomes unstable at any point, proceed to synchronized cardioversion. The critical rule is that AV nodal blocking agents are absolutely contraindicated in this scenario. Adenosine, beta-blockers (metoprolol, atenolol), non-dihydropyridine calcium channel blockers (verapamil, diltiazem), and digoxin must all be avoided. These drugs slow or block conduction through the AV node, which paradoxically enhances conduction through the accessory pathway by removing the "competing" normal pathway. This can accelerate the ventricular rate to lethal speeds, causing ventricular fibrillation.

Long-Term / Definitive Management

The definitive treatment for WPW syndrome is radiofrequency catheter ablation of the accessory pathway. This is performed during an EP study and has a success rate exceeding 95%, with a low complication rate. It is first-line for patients with symptomatic arrhythmias and should be strongly considered for patients with high-risk features on EP study (short accessory pathway refractory period, inducible atrial fibrillation, or multiple accessory pathways). Following successful ablation, the delta wave disappears from the ECG, the PR interval normalizes, and the patient is considered cured.

For patients who refuse or are not candidates for ablation, chronic antiarrhythmic drug therapy with flecainide or propafenone (Class IC agents) may be used, though this is a less favorable long-term strategy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most commonly tested pitfall with WPW is the management of atrial fibrillation with a pre-excited ventricular response. The vignette will describe a young patient with an irregularly irregular wide-complex tachycardia, and the answer choices will include AV nodal blockers such as metoprolol, diltiazem, verapamil, or digoxin alongside procainamide and cardioversion. The trap is selecting an AV nodal blocker, which feels intuitive because students are trained to rate-control atrial fibrillation with these drugs. In WPW, this is lethal. The correct answer is procainamide (if stable) or synchronized cardioversion (if unstable). Expect the exam to test this rule repeatedly and from different angles.

A second common trap involves differentiating orthodromic AVRT from AVNRT. Both present as regular, narrow-complex SVTs in young patients and both respond to adenosine. The key to distinguishing them on the exam is the baseline ECG: if the stem mentions a delta wave, short PR, or pre-excitation at baseline, the diagnosis is WPW with orthodromic AVRT, not AVNRT. If the baseline ECG is normal, think AVNRT.

A third trap is confusing WPW pattern with WPW syndrome. The pattern is an incidental ECG finding in an asymptomatic patient and does not automatically require ablation. The syndrome requires both the ECG findings and symptomatic arrhythmias. Exam questions may present an asymptomatic patient with a delta wave and ask for the next step; the answer is risk stratification (EP study in select cases or observation with patient education), not immediate ablation or empiric drug therapy.

Finally, remember that WPW is associated with Ebstein anomaly. If a vignette describes a young patient with a delta wave on ECG and a displaced tricuspid valve on echocardiography, this association is being tested. Likewise, if a question describes a patient with Ebstein anomaly and palpitations, consider WPW as the underlying arrhythmia mechanism.

The core competency being tested is the ability to recognize pre-excitation on an ECG, correctly classify the arrhythmia type, and apply the critical rule that AV nodal blockers are contraindicated when atrial fibrillation coexists with an accessory pathway.